2-Bromo-3-fluoropyridine

We are 2-Bromo-3-fluoropyridine CAS:40273-45-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2-Bromo-3-fluoropyridine
CAS.NO: 40273-45-8
Synonyms:2-BroMo-3-fluoropyridine;
2-Brom-3-fluor-pyridin;
bromo-2 fluoro-3 pyridine;
3-fluoro-2-bromopyridine;
2-bromo-3-fluoro-pyridine;
Molecular Formula: C5H3BrFN
Molecular Weight: 175.98600
 
Physical and Chemical Properties:
Density: 1.7±0.1 g/cm3
Melting point: /
Boiling point: 173.2±20.0 °C at 760 mmHg
Flash point: 58.6±21.8 °C
Index of Refraction: 1.534
 
Specification:
Appearance: Yellow liquid
Purity:≥98.0%
 
Packing:25 KGS/Drum
Storage:Store in a tightly closed container. Store in a cool, dry
Application:  used in the pharmaceutical intermediate

 2-Bromo-3-fluoropyridine


Related News: From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.5-Bromo-2-methoxy-3-nitropyridine The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.2499-59-4 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.3-bromobenzaldehído CAS:3132-99-8 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
2,3-Difluoroanisole View Details
cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid View Details
2-(4-(2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)propan-2-yl)phenyl)ethanol View Details
2-Bromofluorobenzene manufacturer 2-chloro-4-(naphthalen-2-yl)-6-phenyl-1,3,5-triazine manufacturer Ethyl 2-bromoisobutyrate manufacturer methyl (3S)-3-hydroxytetradecanoate manufacturer phthalic anhydride manufacturer